Janux Therapeutics vs TScan Therapeutics
TScan Therapeutics reported revenue of $10 million in fiscal 2025, about the same as Janux Therapeutics' $10 million in fiscal 2025. Janux Therapeutics' revenue fell 5.5% in its latest year, and TScan Therapeutics' grew 266.6%. Janux Therapeutics had an operating margin of -1576.7%, against -1315.4% at TScan Therapeutics. Free cash flow was −$83 million at Janux Therapeutics and −$140 million at TScan Therapeutics.
Side by side
| Janux Therapeutics | TScan Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $10M | $10M |
| Revenue growth | −5.5% | 266.6% |
| Revenue growth a year, last 5 years | — | 56.4% |
| Gross margin | — | — |
| Operating margin | −1,576.7% | −1,315.4% |
| Net margin | −1,136.2% | −1,256.8% |
| Free cash flow | −$83M | −$140M |
| Free cash flow margin | −832.8% | −1,353.3% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.3% | 15.9% |
| Last close | $10.29 | $0.14 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $457,063 | bought $145,621, sold $0 |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Janux TherapeuticsTScan Therapeutics
Operating margin
Percent of revenue
Janux TherapeuticsTScan Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Janux TherapeuticsTScan Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Janux Therapeutics and TScan Therapeutics pages.